StockData
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. (JBIO) stock

JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$15.49+0.09 (+0.58%)

Close on Nov 18, 2026Market cap $985.12MP/E –Yield –

Jade Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Jade Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$176.98M. For fiscal 2025 it was -$113.54M. The highest annual figure on record is -$8.89M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$113.54M–
FY2024Dec 31, 2024-$74.60M–
FY2023Dec 31, 2023-$81.41M–
FY2022Dec 31, 2022-$53.24M–
FY2021Dec 31, 2021-$23.02M–
FY2020Dec 31, 2020-$8.89M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$39.64M–
Q2 FY2026Jun 30, 2026-$58.92M–
Q1 FY2026Mar 31, 2026-$43.45M–
Q4 FY2025Dec 31, 2025-$34.98M–
Q3 FY2025Sep 30, 2025-$27.40M–
Q2 FY2025Jun 30, 2025-$27.78M–
Q1 FY2025Mar 31, 2025-$23.38M–
Q4 FY2024Dec 31, 2024-$6.40M–
Q3 FY2024Sep 30, 2024-$14.97M–
Q2 FY2024Jun 30, 2024-$26.17M–
Q1 FY2024Mar 31, 2024-$24.62M–
Q4 FY2023Dec 31, 2023-$22.07M–
Q3 FY2023Sep 30, 2023-$21.37M–
Q2 FY2023Jun 30, 2023-$20.34M–
Q1 FY2023Mar 31, 2023-$17.64M–
Q4 FY2022Dec 31, 2022-$15.85M–
Q3 FY2022Sep 30, 2022-$14.15M–
Q2 FY2022Jun 30, 2022-$12.22M–
Q1 FY2022Mar 31, 2022-$11.02M–
Q4 FY2021Dec 31, 2021-$8.27M–
Q3 FY2021Sep 30, 2021-$6.20M–
Q2 FY2021Jun 30, 2021-$5.77M–
Q1 FY2021Mar 31, 2021-$2.78M–
Q4 FY2020Dec 31, 2020-$3.66M–
Q3 FY2020Sep 30, 2020-$2.24M–
Q2 FY2020Jun 30, 2020-$1.63M–

More Jade Biosciences figures

See a number that looks wrong?